Anatara Lifesciences Ltd (AU:ANR) has released an update.
Anatara Lifesciences has initiated Stage 2 of the GaRP-IBS clinical trial across five Australian cities, seeking to build on the promising results from Stage 1, which saw a significant reduction in IBS symptoms in patients. The trial, which is an extension of the Phase II study, is expected to draw strong interest owing to the ongoing need for effective IBS treatments. The company is also exploring additional healthcare opportunities and is in talks with global pharmaceutical firms for its gastrointestinal products.
For further insights into AU:ANR stock, check out TipRanks’ Stock Analysis page.
